The use of paracetamol has been associated with increased risks for urinary
tract cancers and decreased risk for ovarian cancer, although results have
been inconsistent. We conducted a population-based cohort study using data
from the Prescription Database of North Jutland County and the Danish Canc
er Registry. Cancer incidence among 39,946 individuals receiving prescripti
ons for paracetamol was compared with expected incidence based on the North
Jutland population who did not receive paracetamol prescriptions, during a
9-year follow-up period. Standardized incidence ratios (SIRs) with corresp
onding 95% confidence intervals (95% Cis) were calculated for cancers overa
ll and at selected sites. Overall, 2,173 cancers were observed with 1,973 e
xpected, yielding a SIR of 1.10 (95% Cl, 1.06-1.15). Significantly elevated
SIRs were found for cancers of the esophagus (1.9; 95% Cl, 1.3-2.8) and lu
ng (1.6; 95% Cl, 1.4-1.7). Nonsignificantly increased SIRs were observed fo
r cancers of the liver (1.5; 95% Cl, 0.96-2.2), renal parenchyma (1.3; 95%
Cl, 0.9-1.7) and renal pelvis/ureter (1.6; 95% Cl, 0.96-2.6), whereas the S
IR for cancer of the urinary bladder was close to unity (1. 1; 95% Cl, 0.9-
1.4). For ovarian cancer, the SIR was close to expectation (0.9; 95% Cl, 0.
6-1.2) with no evidence of trends with duration of follow-up or number of p
rescriptions. A similar risk pattern was observed after exclusion of person
-time experience following prescription for aspirin or other nonsteroidal a
ntiinflammatory drugs in the study cohort and reference population. Our res
ults do not support a major role for paracetamol in the development of canc
ers of the urinary tract, and we found little evidence of a protective effe
ct of paracetamol against ovarian cancer. The elevated risks for cancers of
the esophagus, lung and liver are most likely a result of confounding vari
ables, but may warrant further investigation. (C) 2002 Wiley-Liss, Inc.